endocrinology update
play

Endocrinology Update Robert J. Rushakoff, MD Professor of Medicine - PowerPoint PPT Presentation

Endocrinology Update Robert J. Rushakoff, MD Professor of Medicine University of California, San Francisco robert.rushakoff@ucsf.edu Feedback control Golden Rule of Endocrinology If overproduction is suspected, try to suppress production.


  1. Etiology of Hypothyroidism  Primary  Hashimoto’s Thyroiditis automimmune +/- goiter  After RAI or surgery for Graves’ disease  subacute thyroiditis  inborn errors of thyroid hormone synthesis Secondary  hypothalamic or hypopituitarism

  2. Thyroid Hormone Preparations  Levothyroxine (T 4 )  most physiologic  treatment of choice  daily dose  t 1/2 1 week  average dose 0.125 mg/day  Formula: 1.6 mcg/kg/day

  3. Thyroid Hormone Preparations  Liothyronine (T 3 )  tid dosing  not physiologic  bypass normal T 4 to T 3 conversion  t 1/2 1 day

  4. Thyroid Hormone Preparations  Desiccated thyroid  potency variable  variable T 4 and T 3 levels  monitoring difficult  bypass normal T 4 to T 3 conversion  80% of patients on this preparation shown not to require any thyroid hormone replacement

  5. Monitoring Thyroid Hormone Replacement Goal is for normal TSH Minimal time after any change in thyroid hormone dose before rechecking TSH level is 6- 8 weeks. It takes this long to reach steady state. More frequent testing will be not only a waste of money but potentially misleading. Decreased Absorption: – Drugs, supplements: calcium, iron, soy, Cholestyramine – Decreased gastric acid: H. pylori infection , omeprazole

  6. Monitoring Thyroid Hormone Replacement TSH Subclinical FT 4 hyperthyroidism Associated with decreased bone density. Associated with atrial arrhythmias in older patients. Patient needs decrease in thyroid hormone dose.

  7. Thyroid Nodules 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer THYROID 26: 1, 2016

  8. Hypopituitarism Although primary organ failure is more common, hypopituitarism is in the differential diagnosis in cases of hypothyroidism, hypoadrenalism and hypogonadism GH, gonadotrophins, TSH, ACTH, Prolactin (loss in this order) ADH deficiency only if posterior pituitary involved

  9. Etiologies – 9 I’s Invasive – tumors, metastasis Infarction – Sheehan’s, apoplexy Iatrogenic – radiation, surgery Infiltrative – sarcoid, hemochromatosis, histiocytosis X Injury – head trauma (also can see DI) Immunologic – lymphocytic hypophysitis Infections – TB, syphilis or fungi Idiopathic Isolated – Kallman’s – GnRH deficiency with anosmia – X linked dominant – decreased expression of KAL 1

  10. Hypopituitarism: Dx and Tx In general, treat underlying cause Central hypothyroidism – TSH is not reliable for screening or for monitoring – Diagnosis depends on low Free T4 – Tx: LT4 therapy, but do not start until adrenal insufficiency has been ruled out

  11. Hypopituitarism: Dx and Tx cont’d Central adrenal insufficiency – Aldosterone secretion intact so no hyperkalemia – Hyponatremia due to decreased GFR & inability to excrete water load (+ increased ADH secretion +/- hypothyroidism) – Dx: cosyntropin stimulation test (random cortisol or ACTH level not useful) – Tx: hydrocortisone 20-30 mg/d, 2/3 in the morning and 1/3 in the evening. Prolactin deficiency – inability to lactate

  12. Pituitary tumors  Microadenomas are < 1cm Macroadenomas are >1cm Types of tumors – 60% prolactinomas – 20% GH producing – 10% ACTH producing – 10% non-functioning – Rare: TSH, LH/FSH or a -subunit producing

  13. Pituitary tumors - Presentation Symptoms/Exam: – Neurological syx (h/a, visual field cuts, nerve palsies) – Hormonal excess or deficiency – Incidental discovery on imaging study up to 10% general population have pituitary incidentalomas

  14. Pituitary tumors - Evaluation Once tumor is identified, must determine if functional or not: – TSH, FT4 – Prolactin – ACTH, cortisol Cosyntropin stimulation test if suspect deficiency 24 hr urinary cortisol or dexamethasone suppression test if suspect excess – LH/FSH + testosterone in men

  15. Hyperprolactinemia

  16. Hyperprolactinemia Physiologic: Pathologic: – Pregnancy (prolactin – Pituitary tumors – can reach 200 ng/ml in mostly 2 nd trimester) microadenomas – Lactation – Pituitary stalk lesions – Nipple stimulation – Hypothalamic lesions – Exercise – Chest wall /spinal cord lesions – Coitus – Hypothyroidism – Stress – Chronic kidney – Sleep disease – Cirrhosis

  17. Hyperprolactinemia Cont’d Pharmacologic: – Estrogen – Dopamine antagonists (phenothiazines, haloperidol, risperidone, metoclopramide, methyldopa, opioids, amoxapine) – Monoamine oxidase inhibitors – Cimetidine and Ranitidine – SSRI’s – Tricyclic antidepressants – Verapamil – Liquorice

  18. Hyperprolactinemia: Syx/exam Women Men galactorrhea, amenorrhea impotence, decreased or oligomenorrhea with libido, galactorrhea (very anovulation and infertility rare) in 90% 91% macroadenoma Amenorrhea: 18% prolactinoma Galactorrhea: 37% Both Prolactinoma local tumor extension Both: 75% Prolactinoma symptoms - headache, Microadenoma: 64% visual field cuts, hypopituitarism

  19. Hyperprolactinemia: Diagnosis Elevated prolactin: – PRL >200 ng/ml virtually diagnostic of prolactinoma – PRL 100-200 usually prolactinoma – PRL 20-100 may be microadenoma but exclude other causes Normal TFT’s and negative pregnancy test MRI of pituitary

  20. Hyperprolactinemia: Treatment Medical – 1 st line in most cases – Dopamine agonists: bromocriptine or cabergoline SE: nausea, fatigue, nasal stuffiness and postural hypotension Surgical: – For patients intolerant or resistant to medications

  21. Pituitary Tumors: GH Tumors 80% are macroadenomas 15% co-secrete prolactin Very rarely (<1% cases), acromegaly due to ectopic GH or GHRH production – Lung CA, carcinoid, or pancreatic islet cell tumors

  22. Pituitary Tumors: GH Tumors Clinical features due to excess IGF-I and mass effect of the tumor. – Hypertension – Glucose intolerance or DM – Increased colonic polyp frequency – Soft tissue proliferation: coarsening of facial features, hand and feet enlargement – Sweaty palms and soles – Carpal Tunnel Syndrome – Hypogonadism – Visual field cuts and h/a’s

  23. Pituitary Tumors: GH Tumors

  24. Gigantism Identical twins, 22 years old, excess GH secretion

  25. Pituitary Tumors: GH Tumors Diagnosis: – Elevated IGF-1 is the hallmark – Dx: oral glucose tolerance test 100 g glucose given 60 minutes GH<1 ng/ml rules out acromegaly – Random GH level not helpful Therapy: – Surgery: curative in 60-80% – Radiation therapy: adjuvant therapy – Medical: Octreotide LAR (SS analog) Pegvisomant (GH receptor antagonist)

  26. Adrenal Insufficiency: Etiologies Primary AI: – Autoimmune – Metastatic malignancy & lymphoma – Hemorrhage: pregnancy, anticoagulation, antiphospholipid antibody syndrome – Infiltrative disorders: amyloid, hemochromatosis – Drugs: ketoconazole, metyrapone, aminoglutethimide, trilostane, mitotane, etomidate – Rare: congenital adrenal hyperplasia, adrenal leukodystrophy Secondary AI: – Iatrogenic: glucocorticoids & anabolic steroids – Pituitary or hypothalamic tumors

  27. AI: Clinical Features Vague syx: – Weakness – Fatigue – Anorexia – Weight loss – Nausea – Vomiting – Diarrhea – Unexplained abdominal pain – Postural lightheadedness

  28. Hyperpigmentation characteristic of primary adrenal insufficiency

  29. AI: Diagnosis Labs: hyponatremia, hyperkalemia, eosinophilia, mild metabolic acidosis, hypercalcemia Step 1: confirm diagnosis – Any random cortisol  18 m g/dl rules out AI – Cortrosyn stimulation test Obtain baseline cortisol and ACTH Inject Cortrosyn 250 m g IM or IV Check cortisol level 45-60 minutes later Normal if post stimulation cortisol  18 m g/dl Step 2: distinguish 1 o from 2 o Step 3: evaluate cause (CT abdomen or MRI pituitary)

  30. AI: Treatment Hydrocortisone 20-30 mg/day – 2/3 in the morning – 1/3 in evening Stress doses: – Minor stress – double usual dose – Major stress: 50 mg IV q 6-8 hrs, and taper For 1 o AI, also need: – Fludrocortisone 0.05-0.1 mg/day

  31. Cushing’s Syndrome Exogenous steroids: #1 cause Endogenous: – Cushing’s disease (70%): due to ACTH secretion from pituitary adenoma – Ectopic ACTH (15%): from non pituitary tissue making ACTH Small cell lung CA most common Bronchial carcinoids – Adrenal (15%): Adenoma Carcinoma Nodular adrenal hyperplasia

  32. Cushing’s Diagnosis 24 h Urine + Cortisol ACTH _ Low (<5) High (>10 pg/ml) Adrenal Pituitary or Ectopic Normal CT Adrenals MRI pituitary _ Petrosal Sinus ACTH + Central Peripheral Ectopic ACTH-producing tumor Pituitary source

  33. Primary Aldosteronism (PA) Accounts for 0.5-10% cases htn Results from autonomous aldosterone prdctn, due to:

  34. Primary Aldosteronism: Features Hypertension Hypokalemia – May be absent – Exacerbated by diuretics Paresthesias if severe hypokalemia Mild alkalosis on laboratories

  35. Primary Aldosteronism: Dx Screening: – Must first replete potassium – Plasma aldosterone (PA)/ Plasma Renin Activity (PRA) ratio >20-25  suggestive Confirmatory test: – Salt load: 1 g NaCl tid for 3 days – 24 hr urine aldosterone>12 mcg/24 hr with concomitant 24 hr urine Na>200 mmol/d

  36. Pheochromocytoma Rare tumors Produce epinephrine and/or norepinephrine Symptoms: – Episodic throbbing in the chest, trunk and head – Headaches – Diaphoresis – Palpitations – Tremor, anxiety, nausea, vomiting, fatigue – Abdominal or chest pain – Weight loss – Cold hands and feet

  37. Pheochromocytoma cont’d In ¼ of cases, hypertension is episodic Orthostasis usually present Rule of 10’s: – 10% normotensive – 10% occur in children – 10% are bilateral – 10% are malignant – 10% are extra-adrenal (called paragangliomas)

  38. Pheochromocytoma cont’d First – make BIOCHEMICAL dx: – 24-hr urinary metanephrine and normetanephrine or plasma free metanephrine (levels usually 2-3 x normal) If biochemical diagnosis made, localize: – CT or MRI of the adrenal – If CT or MRI negative, can use 123 I-MIBG to localize extra-adrenal pheo and mets

  39. Adrenal Incidentalomas Found in ~10% of autopsies Prevalence increases with age 2 questions for evaluation: – Is lesion functioning or not? – Is lesion benign or malignant?

Recommend


More recommend